Results 171 to 180 of about 84,026 (244)

Would You Take an Open-Label Placebo Pill or Give One to Your Child? Findings from a Cross-Sectional Survey. [PDF]

Psychol Res Behav Manag
Schienle A, Seibel A.
europepmc   +1 more source

Does Managerial Ability Improve Environmental Performance and Overall ESG Ratings? The Impact of the European Sustainability Reporting Mandate

Business Strategy and the Environment, EarlyView.
ABSTRACT This study examines the role of managerial ability in driving environmental performance and overall environmental, social, and governance (ESG) ratings in the context of the European Union sustainability reporting regulations. Using a sample of 7242 firm‐year observations over the period 2015–2023, our results indicate a structural change in ...
Mihaela Ionașcu, Ion Ionașcu, Elena Turuianu   +2 more
wiley   +1 more source

Corrigendum: Preoperative Anxiolysis and Treatment Expectation (PATE Trial): open-label placebo treatment to reduce preoperative anxiety in female patients undergoing gynecological laparoscopic surgery - study protocol for a bicentric, prospective, randomized-controlled trial. [PDF]

Front Psychiatry
Wessels J, Klinger R, Benson S, Brenner T, Elsenbruch S, Aulenkamp JL.   +5 more
europepmc   +1 more source

Contemporary and Emerging Therapies in the Management of Refractory Angina: A Clinical Review

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Refractory angina (RA) represents a growing challenge in clinical cardiology, particularly in patients with obstructive coronary artery disease (CAD) who remain symptomatic despite optimal medical therapy and who are not candidates for revascularization.
Alex Angers‐Goulet, Siddhartha Mengi, David Garcia Labbé, Can Manh Nguyen, Jean‐Michel Paradis   +4 more
wiley   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial.

JAMA Pediatr, 2022
Nurko S, Saps M, Kossowsky J, Zion SR, Di Lorenzo C, Vaz K, Hawthorne K, Wu R, Ciciora S, Rosen JM, Kaptchuk TJ, Kelley JM.   +11 more
europepmc   +1 more source

Correction: Placebo Effects of Open-label Verbal Suggestions on Itch.

Acta dermato-venereologica
This corrects the article DOI: 10.2340/00015555-2823.
openaire   +1 more source

Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children

Clinical Pharmacology &Therapeutics, EarlyView.
Baloxavir acid (baloxavir), the active metabolite of the prodrug baloxavir marboxil, is a selective inhibitor of the influenza virus cap‐dependent endonuclease. The population pharmacokinetic (popPK) profile of baloxavir in adults/adolescents has been described previously.
Sylvie Retout, Stefan De Buck, Jacques Gaudreault, Sébastien Jolivet, Vincent Duval, Valérie Cosson, Marie‐Laure Delporte   +6 more
wiley   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source